1.
Risk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study.
Spini Andrea, Giometto Sabrina, Donnini Sandra, Posarelli Matteo, Dotta Francesco, Ziche Marina et al.
Am J OphthalmolNov 202212 citationsCohort Study
This study found bevacizumab and ranibizumab injections carried a higher risk of intraocular pressure increase than aflibercept, suggesting differential glaucoma risk among anti-VEGF agents.